A fading line between academia and industry
When Novartis gave the University of California, Berkeley, $25 million for plant and microbiology research in 1998, there was an uproar.“Commercially sponsored research is putting at risk the paramount value of higher education — disinterested inquiry,” The Atlantic wrote two years later.
Today, that kind of partnership hardly seems unusual. Look no further than the partnership announced last week between GlaxoSmithKline and the top gene-editing researchers at the University of California.
The reason for the shift is simple, STAT’s Matt Herper writes: Opportunities in science today are too big, and with NIH funding decreasing in inflation-adjusted dollars, the idea of not doing the relevant science is too hard to contemplate.
Read more.
Today, that kind of partnership hardly seems unusual. Look no further than the partnership announced last week between GlaxoSmithKline and the top gene-editing researchers at the University of California.
The reason for the shift is simple, STAT’s Matt Herper writes: Opportunities in science today are too big, and with NIH funding decreasing in inflation-adjusted dollars, the idea of not doing the relevant science is too hard to contemplate.
Read more.
No hay comentarios:
Publicar un comentario